WJWei-Yi Jin

Wei-Yi Jin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Wei-Yi Jin has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Fang-Qing Zhang

    Key Laboratory of Bioactive Substances and Resources Utilization of Chinese Herbal Medicine, Ministry of Education, Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100193, China

    1 shared publication
  • Jiashuo Wu

    Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100193, China

    1 shared publication
  • Jing-Xun Wang

    Institute of Medicinal Plant Development

    1 shared publication
  • Wei-Hua Wang

    School of Pharmaceutical Sciences, Key Laboratory of Bioorganic Phosphorus Chemistry and Chemical Biology (Ministry of Education), Tsinghua University, Beijing China

    1 shared publication
  • Xiaoyan Chang

    Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100193, China

    1 shared publication
  • Yue Shi

    Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100193, PR China

    1 shared publication

Latest Publications

  • Open Access

    A Strategy for Screening the Lipid‐Lowering Components in Alismatis Rhizoma Decoction Based on Spectrum‐Effect Analysis

    by Xiao-Yan Chang, Jia-Shuo Wu, Fang-Qing Zhang, Zhuang-Zhuang Li, Wei-Yi Jin, Jing-Xun Wang, Wei-Hua Wang, Yue Shi

    Alismatis Rhizoma decoction (ARD), comprised of Alisma plantago-aquatica subsp. orientale (Sam.) Sam and Atractylodes macrocephala Koidz. at a ratio of 5 : 2, is a classic traditional Chinese medicine (TCM) formula with successful clinical hypolipidemic effect. This paper aimed to explore the major bioactive compounds and potential mechanism of ARD in the treatment of hyperlipidemia on the basis of spectrum‐effect analysis and molecular docking. Nine ARD samples with varying ratios of the constituent herbs were prepared and analyzed by UPLC‐Q‐TOF/MS to obtain the chemical spectra. Then, the lipid‐lowering ability of the nine samples was tested in an oleic acid‐induced lipid accumulation model in human hepatoma cells (HepG2). Grey relational analysis and partial least squares regression analysis were then performed to determine the correlation between the chemical spectrums and lipid‐lowering efficacies of ARD. The potential mechanisms of the effective compounds were investigated by docking with the farnesoid X receptor (FXR) protein. The results indicated that alisol B 23‐acetate, alisol C 23‐acetate, and alisol B appeared to be the core effective components on hyperlipidemia in ARD. Molecular docking further demonstrated that all three compounds could bind to FXR and were potential FXR agonists for the treatment of hyperlipidemia. This study elucidated the effective components and potential molecular mechanism of action of ARD for treating hyperlipidemia from a perspective of different compatibility, providing a new and feasible reference for the research of TCM formulas such as ARD.